Clinical impact of endoscopy in severely thrombocytopenic patients with hematologic malignancy experiencing gastrointestinal bleeding

Table 1 Baseline demographics and characteristics, mean ± SD or n (%)

Variable	No endoscopy, n = 38	Endoscopy, n = 38	P value
Age	62.7 ± 10.5	58.5 ± 15.6	0.17
Gender
Male	24 (63.2)	27 (71.1)	0.46
Female	14 (36.8)	11 (28.9)
BMI	30.8(12.7)	27.2(8.9)	0.15
Ethnicity
White	32 (84.2)	26 (68.4)	0.24
Black	5 (13.2)	11 (28.9)
Asian	1 (2.6)	1 (2.7)
Comorbidities
Hypertension	25 (65.8)	21 (55.3)	0.35
Cardiac	7 (18.4)	13 (34.2)	0.12
Pulmonary	8 (21.1)	3 (7.9)	0.1
CKD	8 (21.1)	7 (8.4)	0.77
Presentation of GI bleeding
Melena	22 (57.9)	30 (78.9)	0.08
Hematemesis	8(21.1)	2 (5.3)	0.09
Hematochezia	8(21.1)	6 (15.8)	0.77
Hematologic disease/malignancy
MDS	7 (18.4)	6 (15.8)	0.76
AML	11 (28.9)	12 (31.6)	0.8
CML	1 (2.6)	3 (7.9)	0.3
ALL	6 (15.8)	5 (13.2)	0.74
Multiple myeloma	7 (18.4)	7 (18.4)	1.0
NHL	2 (5.3)	2 (5.3)	1.0
CLL	1 (2.6)	0 (0)	0.31
Aplastic anemia	2 (5.3)	2 (5.3)	1.0
Myelofibrosis	1 (2.6)	1 (2.6)	1.0

BMI: Body mass index; CKD: Chronic kidney disease; GI: Gastrointestinal; MDS: Myelodysplastic syndrome; AML: Acute myeloid leukemia; CML: Chronic myeloid leukemia; ALL: Acute lymphoblastic leukemia; NHL: Non-Hodgkin lymphoma; CLL: Chronic lymphocytic leukemia.